Pancreatic Cancer (Adenocarcinoma) Pathways

---

**Adjuvant Therapy**

- __Capecitabine (Xeloda) and gemcitabine (Gemzar)__
- __FULV: fluorouracil (5FU) and leucovorin__
- __Gemcitabine (Gemzar)__
- __mFOLFIRINOX*: fluorouracil (5FU), leucovorin, irinotecan (Camptosar), and oxaliplatin__

---

**Locally Advanced/Unresectable and Metastatic Disease | First Line of Therapy (1st Line) | ECOG PS: 0-2**

- __FOLFIRINOX: fluorouracil (5FU), leucovorin, irinotecan (Camptosar), and oxaliplatin__
- __Gemcitabine (Gemzar)__
- __Gemcitabine (Gemzar) and nab-paclitaxel (Abraxane)__

---

**Locally Advanced/Unresectable and Metastatic Disease | Second Line of Therapy (2nd Line) | ECOG PS: 0-2**

- __Gemcitabine (Gemzar)__

---

*Modified FOLFIRINOX: Bolus 5-FU not administered

---

**Note:** Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by health plan formularies, medical policies, or preferred product rules.